ILARIS 150 mg/ml sol inj 150 mg 1 pce

7680700400015 CH-70040 L04AC08 07.15.0.

Active substances:

Canakinumabum

No images available

Details

Product number
7004001
CPT
-
Packaging group
1
Unit
Injektor(en), vorgefüllt/Pen
Composition
canakinumabum 150 mg, mannitolum, histidinum, histidini hydrochloridum monohydricum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml.

Articles (1)

Ilaris 150 mg/ml, Injektionslösung in einem Fertigpen
Injektionslösung in einem Fertigpen
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
16/01/2026
Patient information leaflet
Français
16/01/2026
Patient information leaflet
Italien
16/01/2026

Detailed composition

Substance Quantity Type Category
canakinumabum
150.0 MG Substance Wirkstoff (Principe actif)
mannitolum
- Substance HNIDK
histidinum
- Substance HNIDK
histidini hydrochloridum monohydricum
- Substance HNIDK
polysorbatum 80
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK

Reimbursement information

Public price
CHF 10954.95
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/04/2026

Authorization holder

Novartis Pharma Schweiz AG

6343 Risch

Authorization information

Swissmedic authorization number
70040
Drug name
Ilaris, Injektionslösung in einem Fertigpen
Galenic form
INLFP
ATC Code
L04AC08
Authorization status
Z
Dispensation category
A
First authorization
04/12/2025
Authorization expiration date
03/12/2030
IT number
07.15.0.
Domain
Human medicine
Field of application
Cryopyrin-assoziierte Periodische Syndrome (CAPS) wie des Muckle-Wells-Syndroms (MWS), des familiären autoinflammatorischen Kälte-Syndroms (FACS) / der familiären Kälteurtikaria (FCU) und der multisystemischen entzündlichen Erkrankung mit Beginn im Neugeborenenalter (NOMID)/des chronischen infantilen neuro-dermo-artikulären Syndroms (CINCA). Tumornekrosefaktor-Rezeptor-assoziiertes periodisches Syndrom (TRAPS). Hyperimmunglobulin-D-Syndrom (HIDS) / Mevalonatkinasedefizienz (MKD). Familiäres Mittelmeerfieber (FMF). Systemische juvenile idiopathische Arthritis (SJIA). Adultes Still-Syndrom.

Packaging details

Description (FR)
ILARIS 150 mg/ml sol inj 150 mg 1 pce
Description (DE)
ILARIS 150 mg/ml Inj Lös 150 mg 1 Stk
Market launch
01/04/2026
Narcotic (BTM)
No
Buy us a coffee Explore the data